PharmaShots | Incisive News in 3 Shots

Subscribe Now

approval

Insights+: The US FDA New Drug Approvals in October 2022

Insights+: The US FDA New Drug Approvals in October 2022

November 17, 2022

Samsung Bioepis’s Ontruzant (biosimilar, trastuzumab) Receives the Health Canada Approval for the Treatment of Breast & Gastric Cancer

Samsung Bioepis’s Ontruzant (biosimilar, trastuzumab) Receives the Health Canada Approval for the Treatment of Breast & Gastric Ca...

February 2, 2022

Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval as an Adjuvant Therapy for Renal Cell Carcinoma

Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval as an Adjuvant Therapy for Renal Cell Carcinoma

November 19, 2021

Antengene's Selinexor (ATG-010) Receives NMPA's IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Antengene's Selinexor (ATG-010) Receives NMPA's IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

November 19, 2021

Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval as an Adjuvant Therapy for Renal Cell Carcinoma

Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval as an Adjuvant Therapy for Renal Cell Carcinoma

November 19, 2021

Antengene's Selinexor (ATG-010) Receives NMPA's IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Antengene's Selinexor (ATG-010) Receives NMPA's IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

November 19, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
[email protected]
Newsletter

Our Information

Follow Us